Franklin Genomic Advancements ETF (BATS:HELX) Short Interest Up 108.6% in June

Franklin Genomic Advancements ETF (BATS:HELX) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 15,981 shares, a growth of 108.6% from the June 15th total of 7,660 shares. Currently, 4.0% of the company’s shares are sold short. Based on an average trading volume of 4,418 shares, the days-to-cover ratio is currently 3.6 days.

Franklin Genomic Advancements ETF Trading Up 0.6%

BATS:HELX opened at $39.71 on Thursday. Franklin Genomic Advancements ETF has a twelve month low of $26.99 and a twelve month high of $41.30. The company has a market cap of $15.88 million, a price-to-earnings ratio of 26.71 and a beta of 1.05. The stock has a fifty day simple moving average of $36.45 and a 200-day simple moving average of $35.31.

Institutional Investors Weigh In On Franklin Genomic Advancements ETF

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HELX. Kestra Advisory Services LLC purchased a new stake in Franklin Genomic Advancements ETF in the 4th quarter valued at about $39,000. Raymond James Financial Inc. purchased a new position in shares of Franklin Genomic Advancements ETF during the second quarter worth approximately $42,000. Osaic Holdings Inc. increased its position in shares of Franklin Genomic Advancements ETF by 19.1% during the second quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock worth $87,000 after acquiring an additional 502 shares during the period. Finally, LPL Financial LLC increased its position in shares of Franklin Genomic Advancements ETF by 22.4% during the fourth quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock worth $404,000 after acquiring an additional 2,037 shares during the period.

Franklin Genomic Advancements ETF Company Profile

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.